Drakenterprises

Not clinical advice. Clinical Evidence is a current-awareness feed. It is not a clinical decision-support system, not medical advice, and not a substitute for clinical judgment, institutional protocols, or the original sources. Full text, NCCN recommendations, and Cochrane review bodies are not reproduced here.

All trials

TrialNCT07578571

A Phase 1 Study of IM-1617 in Participants With Advanced Cancer

Status
RECRUITING
Phase
PHASE1
Last update posted
09/04/2026
Start
05/21/2026
Sponsor
Immunome, Inc.
Specialties
oncology

Conditions: Colorectal Cancer; Non-Small Cell Lung Cancer; Breast Cancer; Esophageal Cancer; Stomach Cancer; Cancer

Brief summary

This study will test the safety and effectiveness of a drug called IM-1617 in participants with solid tumors. Participants will have solid tumor cancer that has spread through the body (metastatic) or cannot be removed with surgery (unresectable). This study will have two parts. Part A will test increasing doses of IM-1617 to find out the safe dose and schedule of IM-1617 for participants. Part B will use the dose and schedule found in Part A to further study the safety of IM-1617 and if it works to treat solid tumor cancers.

Protocol documents and results are not hosted here. Verify every detail on ClinicalTrials.gov.

Clinical Evidence